JBJaimanti Bakshi

Jaimanti Bakshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaimanti Bakshi has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the biomarker potential of LCN2 and MMP9 proteins in Head and Neck Squamous Cell Carcinoma

    by Smriti Suri, Monil Parsana, Himanshu Garg, Geeta S. Boora, Anshika Chauhan, Kapil Goel, Shipra Gupta, Suvradeep Mitra, Jaimanti Bakshi, Sushmita Ghoshal, et al.

  • Open Access

    Early Detection of Glottic Cancer Through Machine Learning and Acoustic Voice Analysis: A Systematic Review

    by Himanshu Verma, Roshani Mishra, Banumathy Nagamani, Sourabha Kumar Patro, Anurag Snehi Ramavat, Jaimanti Bakshi, Padmavati Khandnor, Sudesh Rani, Trilok Chand

    Purpose: Early detection of glottic cancer is essential for better outcomes, but current diagnostic methods remain largely invasive, highlighting the need for reliable non-invasive alternatives. Acoustic voice signals offer a non-invasive screening input, but their clinical value depends on whether signal-processing features and learned models can distinguish malignancy from acoustically similar benign lesions rather than merely separate pathological from healthy voices. Despite growing research on acoustic analysis combined with machine learning (ML) techniques, no systematic synthesis of this evidence currently exists. Therefore, the present review aimed to identify acoustic features that differentiate early glottic malignancies from both benign vocal fold lesions and normal vocal function using various ML techniques. Method: Following PRISMA 2020 guidelines, a comprehensive literature search was conducted across Scopus, EBSCO, Ovid (Embase), and PubMed databases through November 2025. Eighteen studies met inclusion criteria, and PROBAST was used for quality appraisal of included studies. Data extraction focused on acoustic feature categories, ML techniques, classification performance metrics, and validation strategies. Results: Nine acoustic feature categories emerged, with cepstral coefficients (particularly MFCCs) most prevalent across 55.6% of studies. Binary pathological-versus-normal classification achieved consistently high accuracy (96–98.3%) across both traditional machine learning and deep learning approaches. However, malignant-versus-benign discrimination demonstrated substantially lower performance (81–87.88% accuracy, AUC 0.631–0.91), with voice-only models proving insufficient. Multimodal models incorporating clinical variables or laryngoscopic images achieved higher performance, but their results cannot be attributed to voice features alone. All 17 prediction studies were judged at high overall risk of bias, predominantly because of small effective sample sizes, model-selection optimism, possible data leakage, and limited independent validation. Conclusions: ML can detect broad voice pathology, but current evidence is insufficient to support stand-alone acoustic screening for early glottic cancer. Future studies require clearly defined cancer-specific targets, patient-level analysis, standardized acquisition, nested model development, calibration, and independent multicentervalidation.

  • Clinicopathological predictors of radioiodine response in differentiated high-grade thyroid carcinoma

    by Sohini Banerjee, Uma Nahar Saikia, Apurva Sood, Piyush Aggarwal, Soham Mukherjee, Pinaki Dutta, Divya Dahiya, Rijuneeta Gupta, Satyawati Mohindra, Jaimanti Bakshi

  • Open Access

    Cochlear Implantation in Arnold–Chiari Malformation Type 1: Expanding the Boundaries of Pediatric Neuro-Otology

    by Jaimanti Bakshi, Sukriti Nehra, Krishna Gharti, Ritik Arora, Dharam Vir, Noorain Alam, Vikas Saini, Ishita Sood

    Arnold–Chiari malformation (ACM) is a rare congenital hindbrain anomaly, with types 1-4 depending of degree of herniation of posterior fossa contents. The incidence of type 1 ACM is highest, with most cases being asymptomatic. Cases are incidentally picked up; however, some may present with headache, cough, paresthesia, and very rarely, symptoms of compression of lower cranial nerves such as sensorineural hearing loss. Surgical challenges are anticipated due to associated skeletal malformations and raised intracranial pressure. The youngest reported case—a 3-year-old girl with delayed speech and language milestones—is presented, in whom ACM type 1 was incidentally diagnosed. Audiological workup revealed profound sensorineural hearing loss in both ears. After multidisciplinary clearance, she underwent right-sided cochlear implantation. Intraoperative challenges faced were dilated emissary veins, an anteriorly placed sigmoid sinus, and a low-lying dura. However, a full electrode insertion was achieved and confirmed on neural response telemetry. The postoperative course was uneventful. Literature review suggests this to be the youngest reported case of cochlear implantation in ACM type 1. While hearing loss in this case may have been unrelated to ACM, nonetheless, successful cochlear implantation is feasible with meticulous preoperative planning and intraoperative vigilance. After a thorough anatomical assessment, multidisciplinary preoperative workup, intraoperative vigilance, and neuro-anesthetist backup, cochlear implantation can be safely performed in children with ACM type 1.

  • Open Access

    Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma

    by Geeta S. Boora, Anshika Chauhan, Rijuneeta Gupta, Jaimanti Bakshi, Sushmita Ghoshal, Arnab Pal

    Metastatic dissemination is driven by rare Circulating Tumour Cells (CTCs) that exhibit pronounced phenotypic plasticity and dynamic interactions with different components in the bloodstream. In Oral Squamous Cell Carcinoma (OSCC), limited resolution of epithelial, mesenchymal, and platelet-associated CTC-states has constrained biological understanding of early tumour spread and hindered translational interpretation. In this study, we identify, count and characterize distinct epithelial, mesenchymal, and platelet-associated CTC-states in a cohort of 33 patients using a strategic workflow involving hematopoietic cell depletion with multiparametric flow-cytometric analysis. The FACS (Fluorescence-assisted cell sorting)-strategy incorporated epithelial tumour-associated markers (EpCAM, EGFR, and Cytokeratin), mesenchymal markers (VIM and N-Cadherin), and platelet/leukocyte markers (CD41 and CD45) to resolve biologically distinct CTC-subpopulations. Analytical robustness was established through spike-in experiments using OSCC cell line i.e., Cal27, demonstrating linear detection across clinically relevant ranges(1-100cells/mL of blood, Spearman’s r = 0.8738, p < 0.0001) and sensitive recovery of rare tumour cells with a Limit of Detection of 1 cell/mL, Limit of Quantification of 10 cells/mL, and Limit of Blank of 1.779 cells/mL. Molecular validation of sorted populations using whole transcriptome amplification-quantitative PCR confirmed tumour-associated marker expression and absence of hematopoietic contamination. Application of this approach in OSCC patients revealed detectable CTCs in 70% of the cases (ranging from 14.20 to 340.5 CTCs-related events/mL). Importantly, CTCs were identified across discrete phenotypic states, including platelet-associated CTC-clusters that were not captured by epithelial marker-restricted strategies. Quantitative comparison of CTC subtype proportions revealed majority (nearly 83%) of CTCs present as platelet clusters, followed by Epithelial-Single CTCs (21.21%). In comparison, CTCs with only mesenchymal phenotype constitute only 3.22% of the total CTC-population. Receiver operating characteristic analysis supported the discriminatory capacity of CTC enumeration and enabled the definition of a biologically relevant threshold of > 19.40 events mL for CTC positivity. Taken together, our findings outline a practical workflow for identifying and quantifying different CTC-states in OSCC, with platelet-associated CTCs emerging as the predominant population detected. These findings support the importance of incorporating phenotypic heterogeneity and platelet-associated tumour cell interactions into future liquid biopsy-based translational pathology research and clinical biomarker development in OSCC.

  • Behavioural Challenges and Parental Stress in Children with Cochlear Implants: A Psychosocial Study

    by Noorain Alam, Kritika Arora, Asha Gupta, Sanjay Munjal, N. Banumathy, Dharam Vir, Jaimanti Bakshi

  • Impact of Cochlear Radiotherapy Dose on Hearing Loss in Carcinoma Oropharynx Treated by Concurrent Chemoradiotherapy Using Simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB -VMAT)

    by A. Lokeswari, Amit Bahl, N. Banumathy, Jaimanti Bakshi, Satyawati Mohindra, Rijuneeta Gupta, Ghoshal Sushmita, Oinam Arun Singh, Ranjit Singh, Naresh Kumar Panda

    This study evaluates the impact of reduction of radiotherapy dose received by cochlea on hearing loss in oropharyngeal cancer patients treated by concurrent cisplatin chemoradiotherapy using simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB-VMAT). Sixty ears were evaluated in this prospective non blinded randomized trial. The study group (n=30) was treated with concurrent chemoradiotherapy using Image Guided Radiotherapy with Simultaneous Integrated Boost-Volumetric Modulated Arc technique. The matched control group (n=30) received concurrent chemoradiotherapy using 3D conformal radiotherapy (3DCRT). Concurrent chemotherapy was given to all patients with injection Cisplatinum 100 mg/m2 on D1,22&43 along with radiotherapy. Baseline hearing evaluation was done using puretone, impedence and high frequency audiometry. The tests were repeated at 6 months follow up to evaluate hearing loss. The mean radiotherapy dose received by the right and left cochlea in the 3DCRT and SIB-VMAT techniques was 38.99±4.78 versus 6.97±6.09 Gy (mean±SD) (p=0.001) and 38.59±5.10 versus 6.79±5.76 Gy (p=0.001). At 6 months of follow up sensorineural hearing loss was observed in 66.7 versus 0% (p=0.001) and 86.7 versus 6.7% (p=0.001) in the right and left ear in the 3DCRT and SIB-VMAT groups.High risk PTV 66 volume more than 300 cc was associated with a higher risk of hearing loss with odds ratio of 6.05 (95% CI 0.54-67.53) and 4.41(95% CI 0.52-37.16) in right and left ear. Age more than fifty years was associated with significant hearing loss in the right ear with an odds ratio of 12.56 (95% CI 0.84-187.87) (p=0.02) and 7.38 (95% CI 0.74-73.59) for the left ear. The study shows that reduction in radiotherapy dose received by cochlea is an independent determinant in reducing ototoxicity in the setting of concurrent single agent cisplatin chemotherapy. High risk PTV volume more than 300 cc was associated with a significant increase in hearing loss and PTV 66 volume emerged as a predictive factor for treatment related hearing loss.


  • Precision and Pitfalls: A Prospective Study Analysing the Immediate Postoperative Sequelae and Oncological Outcome of TORS When Used in Diagnostic Algorithm of Carcinoma Unknown Primary

    by Naresh Kumar Panda, Karthika Chettuvatti, Jaimanti B. Bakshi

    With the realm of carcinoma unknown primary, incorporating Trans Oral Robotic Surgery represents the diagnostic frontier. This study emphasises the immediate postoperative sequelae and also oncological outcome of patients who underwent TORS to diagnose the primary site in unknown primary carcinoma and assesses the feasibility in the Indian scenario. A prospective study was carried out at a tertiary care centre over two years (January 2020 to January 2022). Patients underwent TORS-assisted ipsilateral radical tonsillectomy, tongue base mucosal wedge biopsy and neck dissection as a part of the diagnostic algorithm of carcinoma unknown primary. The postoperative complications, need for nasogastric feeding, need for tracheostomy, return to oral diet and duration of hospital stay were assessed in these patients. Oncological outcomes were assessed in the same population with the median follow up duration of 49 months. The study encompassed a group of 18 patients of Carcinoma Unknown Primary (CUP) who underwent a comprehensive set of procedures, including ipsilateral radical tonsillectomy, mucosal tongue base wedge biopsy, and neck dissection for the identification of the primary site. The average duration of inpatient stay post-surgical procedure was 3.33 ± 0.57 days. A late postoperative complication of Transoral Robotic Surgery (TORS) manifested as minor intraoral bleeding in 11.1% of patients (n = 2/18). An immediate postoperative complication related to neck dissection, specifically neck hematoma, occurred in 11.76% of patients (n = 2/17). Tracheostomy and nasogastric feeds were implemented for a short period in only 5.9% of patients (n = 1/17). Survival analysis conducted on the same population, with a median follow-up of 33 months, revealed no differences in Overall Survival (OS) and Disease-Free Survival (DFS) concerning primary site identification and HPV positivity. Transoral Robotic Surgery (TORS) with concurrent neck dissection proves to be an effective diagnostic and concurrent treatment option for patients with Carcinoma of unknown primary (CUP) with secondary squamous cell neck metastasis. This minimally invasive approach shows a 3-year overall survival rate of 88.69% and a disease-free survival rate of 89.12% with median follow up duration of 33 months.

  • Surgical Puzzle: Concurrent Comprehensive Neck Dissection Strategies Unravelling the Mystery of Carcinoma Unknown Primary when Performed with TORS Radical Tonsillectomy and Mucosal Tongue Base Wedge Biopsy in Northern Indian Cohort

    by Naresh Kumar Panda, Karthika Chettuvatti, Jaimanti B. Bakshi

    The study delves into the distribution of cervical nodal metastasis among patients diagnosed with carcinoma of unknown primary who underwent definitive diagnostic surgical management in form of transoral robotic surgery assisted ipsilateral radical tonsillectomy and tongue base mucosal wedge biopsy with concurrent therapeutic open ipsilateral neck dissection. We conducted a prospective study at a tertiary care center over two-years, enrolling patients with unilateral neck swelling histopathologically confirmed as squamous cell carcinoma neck metastasis. For cases where the primary site remained undetected despite evaluation, patients underwent Transoral Robotic Surgery (TORS) assisted ipsilateral radical tonsillectomy and tongue base wedge biopsy, along with concurrent open ipsilateral neck dissection. The study examines the clinicopathological correlation of nodal metastasis in carcinoma of unknown primary and explores the concepts of Lymph node yield (LNY) and Lymph node density (LND). Clinicoradiologically, the majority of patients exhibited N2b disease (n = 10/18, 55.55%). However, histopathological examination of the neck dissection specimen revealed N3b disease in the majority (n = 5/17, 29.4%). Neck dissection was aborted for 1 patient with unresectable N3b nodal metastasis during the procedure. The most commonly affected lymph node level clinicoradiologically was level II (n = 18/18, 100%), which corresponded to level II pathologically in most cases (n = 15/18, 88.2%). Ipsilateral radical neck dissection was required in the majority of cases (n = 10/17, 58.82%). The median Lymph Node Yield (LNY) from ipsilateral neck dissection was 30.78 ± 3.52, with the highest Lymph Node Ratio (LNR) detected from level II (11.1 ± 1.56). In the context of carcinoma of unknown primary with secondary neck metastasis, exploring emerging concepts such as Lymph Node Ratio (LNR) and Lymph Node Density (LND) alongside other clinicopathological parameters is crucial. These concepts provide valuable insights into the metastatic burden and may aid in refining prognostication and treatment strategies for patients with this condition.